Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Clinuvel Pharmaceuticals Limited (AU:CUV)
ASX:CUV
RESEARCH TOOLSreports
Holding AU:CUV?
Track your performance easily
CUV Stock Chart & Stats
Day’s RangeAU$0 - AU$0
52-Week RangeAU$12.96 - AU$18.20
Previous CloseAU$14.98
Volume6.69K
Average Volume (3M)83.15K
Market Cap
AU$750.17M
Enterprise ValueAU$629.91M
Total Cash (Recent Filing)AU$121.51M
Total Debt (Recent Filing)AU$1.26M
Price to Earnings (P/E)21.2
Beta0.65
Next Earnings
Feb 25, 2025EPS Estimate
AU$0.21Last Dividend Ex-Date
Sep 05, 2024Dividend Yield0.33%
Share Statistics
EPS (TTM)0.71
Shares OutstandingN/A
10 Day Avg. Volume73,705
30 Day Avg. Volume83,154
Standard Deviation0.13
R-Squared0.06
Alpha-0.00372
Financial Highlights & Ratios
Price to Book (P/B)0.00
Price to Sales (P/S)15.82
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$27.26Price Target Upside83.54% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Clinuvel Pharmaceuticals Limited News
PremiumCompany Announcements
Clinuvel Highlights SCENESSE® Success at ICPP 2024
PremiumCompany Announcements
Clinuvel Continues Share Buy-Back Effort
PremiumCompany Announcements
Clinuvel Pharmaceuticals Announces 2024 AGM
PremiumCompany Announcements
Clinuvel AGM Time Changed, Company Thrives
PremiumCompany Announcements
Clinuvel Appoints New Director, No Securities Held
PremiumCompany Announcements
Clinuvel Appoints New Director, Guy van Dievoet
PremiumCompany Announcements
Clinuvel Pharmaceuticals Appoints New Director
PremiumCompany Announcements
Clinuvel Continues Share Buy-Back InitiativeOptions Prices
Currently, No data available
---
Ownership Overview
22.44% Insiders
2.80% Mutual Funds
2.58% Other Institutional Investors
72.18% Public Companies and
Individual Investors
CUV FAQ
What was Clinuvel Pharmaceuticals Limited’s price range in the past 12 months?
Clinuvel Pharmaceuticals Limited lowest share price was AU$12.96 and its highest was AU$18.20 in the past 12 months.
What is Clinuvel Pharmaceuticals Limited’s market cap?
Currently, no data Available
When is Clinuvel Pharmaceuticals Limited’s upcoming earnings report date?
Clinuvel Pharmaceuticals Limited’s upcoming earnings report date is Feb 25, 2025 which is in 158 days.
How were Clinuvel Pharmaceuticals Limited’s earnings last quarter?
Clinuvel Pharmaceuticals Limited released its earnings results on Aug 29, 2024. The company reported AU$0.494 earnings per share for the quarter, beating the consensus estimate of AU$0.441 by AU$0.053.
Is Clinuvel Pharmaceuticals Limited overvalued?
According to Wall Street analysts Clinuvel Pharmaceuticals Limited’s price is currently Undervalued.
Does Clinuvel Pharmaceuticals Limited pay dividends?
Clinuvel Pharmaceuticals Limited pays a Annually dividend of AU$0.05 which represents an annual dividend yield of 0.33%. See more information on Clinuvel Pharmaceuticals Limited dividends here
What is Clinuvel Pharmaceuticals Limited’s EPS estimate?
Clinuvel Pharmaceuticals Limited’s EPS estimate is AU$0.21.
How many shares outstanding does Clinuvel Pharmaceuticals Limited have?
Clinuvel Pharmaceuticals Limited has 50,077,780 shares outstanding.
What happened to Clinuvel Pharmaceuticals Limited’s price movement after its last earnings report?
Clinuvel Pharmaceuticals Limited reported an EPS of AU$0.494 in its last earnings report, beating expectations of AU$0.441. Following the earnings report the stock price went up 10.863%.
Which hedge fund is a major shareholder of Clinuvel Pharmaceuticals Limited?
Currently, no hedge funds are holding shares in AU:CUV
---
Clinuvel Pharmaceuticals Limited Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
AU$27.26 (83.54% Upside)
AU$27.26 (83.54% Upside)
Blogger Sentiment
Bullish
AU:CUV Sentiment 92%
Sector Average 71%
Sector Average 71%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-2.31%
12-Months-Change
Fundamentals
Return on Equity
19.08%
Trailing 12-Months
Asset Growth
19.70%
Trailing 12-Months
Company Description
Clinuvel Pharmaceuticals Limited
Clinuvel Pharmaceuticals Ltd. is a global biopharmaceutical company. It engages in the the development of SCENESSE, its proprietary photoprotective drug. It also offers drugs for the treatment of various skin disorders. The company was founded by Robert Thomas Dorr on December 14, 1999 and is headquartered in Melbourne, Australia.
---
CUV Company Deck
---
CUV Earnings Call
Q4 2024
0:00 / 0:00
---
CUV Stock 12 Month Forecast
Average Price Target
AU$27.26
▲(83.54% Upside)
Technical Analysis
Clinuvel Pharmaceuticals Limited
―
ACADIA Pharmaceuticals
―
Arrowhead Pharmaceuticals
―
Assertio Therapeutics
―
Aurinia Pharmaceuticals
―
Best Analysts Covering CUV
1 Year
1 Year Success Rate
7/15 ratings generated profit
1 Year Average Return
-6.56%
reiterated a buy rating 21 days ago
Copying Melissa Benson's trades and holding each position for 1 Year would result in 46.67% of your transactions generating a profit, with an average return of -6.56% per trade.
---